|
|
Vaccine Detail
|
MAGE-A3 + AS15 |
| Vaccine Information |
- Vaccine Name: MAGE-A3 + AS15
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007636
- Type: Subunit vaccine
- Status: Clinical trial
- Antigen: tumor-specific MAGE-A3 antigen
- Preparation: MAGE-A3 combined with AS15
- Immunization Route: Intramuscular injection (i.m.)
- Description: In the MAGE-A3+AS15 arm, clinical activity was higher and the immune response more robust. Therefore, the AS15 immunostimulant was selected for combination with the MAGE-A3 protein in phase III trials (Kruit et al., 2013).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: No reliable correlation at the individual level can be inferred between clinical response and increased amplitude of an antigen-specific CD4+ T-cell response. This observation is in line with results of other studies evaluating MAGE-A3 (Kruit et al., 2013).
|
| References |
Kruit et al., 2013: Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(19); 2413-2420. [PubMed: 23715572].
|
|
